title: IL-4, IL-10 and high sensitivity-CRP as potential serum biomarkers of persistent/recurrent disease in papillary thyroid carcinoma with/without Hashimoto's thyroiditis.
abstract: OBJECTIVE
  To investigate the potential role of interleukin 4 (IL-4), interleukin 10 (IL-10) and high-sensitivity C-reactive protein (hs-CRP) as serum biomarkers of persistent/recurrent disease in papillary thyroid carcinoma (PTC) with/without Hashimoto's thyroiditis (HT).
  
  
  METHODS
  Eighty consecutive patients (64 F/16 M, 43.2 ± 12.7 years) with PTC and 40 (37 F/3 M, 40.6 ± 12.3 years) with papillary thyroid carcinoma associated with Hashimoto's thyroiditis (PTC + HT) were evaluated before radioiodine therapy. A control group of 20 patients with HT without thyroid cancer (18 F/2 M, 47.3 ± 2.8 years) was included in the study for the comparison of cytokine levels.
  
  
  RESULTS
  No meaningful differences were found in clinical outcomes between PTC and PTC + HT groups (47.5% vs. 45% persistent/recurrent disease). Serum IL-4, IL-10 and hs-CRP levels were higher in patients with persistent/recurrent disease compared to those without recurrence (p < 0.001). IL-4, IL-10 and hs-CRP were also found in substantially higher concentrations in PTC + HT patients with persistent/recurrent disease than in patients with HT or PTC (with or without recurrence) (p < 0.01). Positive correlations were observed between IL-4, IL-10, hs-CRP and thyroglobulin (Tg) (r between 0.48 and 0.56, p < 0.005) or antithyroglobulin antibodies (TgAb) (r between 0.63 and 0.80, p < 0.002) in PTC and PTC + HT patients with persistent/recurrent disease.
  
  
  CONCLUSIONS
  Increased levels of serum IL-4, IL-10 and hs-CRP are associated with persistent/recurrent disease in PTC and PTC + HT patients. Our results suggest that these biomarkers might be used to improve patient stratification according to the risk of recurrence, especially in patients with PTC + HT, where Tg levels are not reliable due to presence of TgAb.
authors: a Department of Carcinogenesis and Molecular Biology , Institute of Oncology Bucharest , Bucharest , Romania.
authors: Adina E
authors: AE
authors: Stanciu
authors: Nafija
authors: N
authors: Serdarevic
authors: Anca E
authors: AE
authors: Hurduc
authors: Marcel M
authors: MM
authors: Stanciu
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood*; D002097:C-Reactive Protein / Q000378:metabolism*; D002277:Carcinoma / Q000150:complications / Q000175:diagnosis* / Q000378:metabolism; D002291:Carcinoma, Papillary; D005260:Female; D050031:Hashimoto Disease / Q000150:complications / Q000175:diagnosis* / Q000378:metabolism; D006801:Humans; D016753:Interleukin-10 / Q000097:blood*; D015847:Interleukin-4 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012680:Sensitivity and Specificity; D013954:Thyroglobulin / Q000097:blood; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D016753:Interleukin-10; D015847:Interleukin-4; D002097:C-Reactive Protein; D013954:Thyroglobulin
keywords: Biological markers; C-reactive protein; Hashimoto disease; interleukins; neoplasm recurrence; thyroid neoplasms